The second candidate, PAR5/PWAR5 (Prader Willi/Angelman region RNA 5), has also been associated with other carcinomas, and acts by reducing EZH2 activity, although its potential role in HCC awaits validation. This evidence concerns the gene PWAR5 and carcinoma.